CBLC100 

CBLC100 is an anticancer compound that targets FACT, while inhibiting NF-κB and activating p53. CBLC100 induces cytotoxicity through p53-dependent apoptotic and non-apoptotic pathways. CBLC100 is applicable to the research of cancers such as fibrosarcoma^[1].

CBLC100 potently activates p53 and inhibits NF-κB in cell-based reporter gene assays, with corresponding EC₅₀ values of 0.03 μM and 0.06 μM^[1].
CBLC100 exerts selective cytotoxicity against human fibrosarcoma HT1080 cells, while showing low toxicity toward normal human Wi38 diploid fibroblasts^[1].
CBLC100 (0.2 μM; 1 h) traps the FACT complex on the chromatin of human fibrosarcoma HT1080 cells, while depleting soluble FACT subunits in the nucleoplasm^[1].
CBLC100 enhances CK2-mediated phosphorylation of the C-terminal region of p53 in human fibrosarcoma HT1080 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

374.48

C₂₄H₂₆N₂O₂

1197996-83-0

O=C1CCC2=C1C=CC3=C2C4=C(C=CC5=C4CCC5=O)N3CCN(CC)CC

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gasparian AV, et al. Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. Sci Transl Med. 2011 Aug 10;3(95):95ra74.  [Content Brief]